<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189631</url>
  </required_header>
  <id_info>
    <org_study_id>AERO-MB02</org_study_id>
    <nct_id>NCT00189631</nct_id>
  </id_info>
  <brief_title>UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Européenne de Recherche en Oncologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Européenne de Recherche en Oncologie</source>
  <brief_summary>
    <textblock>
      To compare maintenance therapy to observation in metastatic breast cancer patients responding&#xD;
      (or stabilized) after 1st-line chemotherapy. Main endpoint is disease-free survival.&#xD;
      Secondary endpoints are overall survival and tolerance. A total of 200 patients will be&#xD;
      included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UFT/LV</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Observation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  metastatic breast cancer&#xD;
&#xD;
          -  objective response or stabilisation after 6 to 8 cycle of a first line chemotherapy&#xD;
&#xD;
          -  time period between the end of chemotherapy and randomization &lt; 4 weeks&#xD;
&#xD;
          -  age over 18 years&#xD;
&#xD;
          -  Performance status (OMS) &lt; 2.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Biological criteria before randomization: Neutrophiles &gt; 1.5 x 109 G/L; Pl. &gt; 100 x&#xD;
             109 G/L; Hb &gt; 10 g/dl; Creatininemia &lt; 1,5 UNL; Bili. &lt; 2 UNL; Transaminases &lt; 2,5&#xD;
             UNL; Alcalines Phosphatases &lt; 2,5 UNL&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer having received more than one chemotherapy line.&#xD;
&#xD;
          -  Tumor progression under chemotherapy&#xD;
&#xD;
          -  Free interval between primary tumor and metastases &gt; 5 years, with estrogen receptors&#xD;
             and without visceral metastases&#xD;
&#xD;
          -  Free interval between primary tumor and metastases &lt; 18 months after adjuvant&#xD;
             chemotherapy if first lime chemotherapy only led to a tumor stabilization&#xD;
&#xD;
          -  Concomitant hormonotherapy&#xD;
&#xD;
          -  Other cancer&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Any uncontrolled severe disease except breast cancer (especially cardiac failure with&#xD;
             LVEF &lt; 50% or coronary insufficiency&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Other concomitant trial&#xD;
&#xD;
          -  Male patient&#xD;
&#xD;
          -  Pregnancy and breast-feeding (effective contraception is mandatory in the case of&#xD;
             women of child-bearing potential)&#xD;
&#xD;
          -  History of high dose chemotherapy with bone marrow transplantation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Berdah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AERO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Zelek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AERO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Audhuy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AERO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Jouhaud</last_name>
    <phone>+ 33 1 43 77 72 10</phone>
    <email>annie.jouhaud@aero-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>AERO</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Zelek, MD</last_name>
      <phone>+ 33 1 43 77 72 10</phone>
      <email>laurent.zelek@hmn.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 7, 2005</last_update_submitted>
  <last_update_submitted_qc>December 7, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

